Developmental Neurotoxicity of Perfluorinated Chemicals Modeled in Vitro by Slotkin, Theodore A. et al.
716 VOLUME 116 | NUMBER 6 | June 2008 • Environmental Health Perspectives
Research
Perﬂuoroalkyl acids (PFAAs) are in use as sur-
factants; also, they are formed as breakdown
products of larger polymers in industrial use,
and they accumulate in the environment
because of their chemical stability and general
lack of biodegradation (Lau et al. 2004, 2006,
2007). There is increasing concern over the
body burdens of these agents in both wildlife
and humans, driven not only by their produc-
tion and release into the environment but also
because of their extremely long biologic reten-
tion times (D’Eon et al. 2006; D’Eon and
Mabury 2007; Lau et al. 2004, 2006, 2007;
Schroder 2003; Schultz et al. 2006; Xu et al.
2004, 2006). For example, the human half-
lives for two of the most prevalent PFAAs,
perfluorooctane sulfonate (PFOS) and
perfluorooctanoic acid (PFOA), are in the
range of 4–6 years (Lau et al. 2007; Olsen
et al. 2007). Serum levels in production work-
ers typically average 0.5–2 µg/mL, with the
highest reported values reaching 13 µg/mL
(26 µM) for PFOS and 114 µg/mL (276 µM)
for PFOA (Lau et al. 2007; Olsen et al. 1998,
1999, 2003a, 2003b). In the general popula-
tion, average values recorded in 2003–2004
were about 20 ng/mL for PFOS and 4 ng/mL
for PFOA, down by about one-third from
those reported in 1999–2000 (Calafat et al.
2007a, 2007b). North American wildlife
populations now show values well into the
tens of micromolar range (Lau et al. 2007).
Although 3M (St. Paul, MN) has phased out
production of PFOS, and PFOA and PFOA
precursor compounds have been committed
to a voluntary phase-out (U.S. Environmental
Protection Agency 2006), the resistance of
these compounds to degradation will result in
their persistence in the environment for many
years. Further, the newer fluorochemicals,
such as perﬂuorobutane sulfonic acid (PFBS),
which were introduced as replacement for
PFOS or PFOA because of their shorter half-
lives in people (3M 2007; Lau et al. 2007),
need to be evaluated for potential common
mechanisms of action.
Despite the highly polar nature of their
sulfonyl or carboxyl head groups, PFOS and
PFOA enter the developing brain, possibly
reﬂecting either their surfactant properties or
the immaturity of the fetal/neonatal blood–
brain barrier (Lau et al. 2004, 2006, 2007).
Accordingly, these agents need to be evaluated
for their potential to elicit developmental
neurotoxicity. Developmental toxicity in
rodents given high doses of PFOS leads to
neonatal morbidity and mortality but also
elicits neurologic delays (Lau et al. 2003;
Luebker et al. 2005a, 2005b). Recently,
Johansson et al. (2008) found that much
lower developmental exposures of mice to
PFOS and PFOA produced behavioral defects
persisting into adulthood, speciﬁcally involv-
ing acetylcholine (ACh) systems, as inferred
from altered responses to nicotine; this sug-
gests that brain development is indeed affected
at exposures below those required for systemic
toxicity. Nevertheless, these studies cannot dis-
tinguish whether the neurodevelopmental
effects of the perﬂuorinated chemicals repre-
sent direct neurotoxic mechanisms as opposed
to indirect consequences of antithyroid
actions, effects on peroxisome proliferator
receptor-α, effects on maternal–fetal or mater-
nal–neonatal physiology or behavior, neonatal
hypoxic episodes from compromised respira-
tory function (as reported at higher exposures),
or any of the myriad possibilities from cryptic
or overt systemic toxicity (Lau et al. 2004,
2006, 2007). One approach to identify direct
developmental neurotoxicity is to use an
in vitro model, where these confounding fac-
tors do not operate. In one study, PFOS was
shown to impair cerebellar Purkinje cell func-
tion in vitro; although this did not involve pro-
tracted effects or neurodevelopment, it pointed
out the potential for direct actions of perﬂuori-
nated chemicals on neuronal cells (Harada
et al. 2006).
In the present study, we used PC12 cells, a
standard in vitro model for neuronal develop-
ment (Teng and Greene 1994) that has already
been used to characterize essential features of
the developmental neurotoxicity of diverse
compounds such as organophosphate and car-
bamate pesticides, organochlorines, metals,
neuroactive drugs, oxidative stressors, and a
host of other agents (Bagchi et al. 1995; Costa
1998; Crumpton et al. 2000b, 2001; Flaskos
et al. 1994; Li et al. 1999; Qiao et al. 2003;
Ramesh et al. 1999; Slotkin et al. 2007; Song
et al. 1998; Tuler et al. 1989). As transformed
cells, the PC12 line has an advantage over cul-
tured primary neurons, which do not maintain
cell division and thus cannot detect adverse
effects on the cell cycle, a likely neurotoxic tar-
get. Furthermore, primary neurons do not pro-
vide a uniform population either in terms of
cell types or differentiation state, rendering
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BACKGROUND: The widespread detection of perﬂuoroalkyl acids and their derivatives in wildlife
and humans, and their entry into the immature brain, raise increasing concern about whether these
agents might be developmental neurotoxicants.
OBJECTIVES: We evaluated perfluorooctane sulfonate (PFOS), perfluorooctanoic acid (PFOA),
perﬂuorooctane sulfonamide (PFOSA), and perﬂuorobutane sulfonate (PFBS) in undifferentiated
and differentiating PC12 cells, a neuronotypic line used to characterize neurotoxicity.
METHODS: We assessed inhibition of DNA synthesis, deﬁcits in cell numbers and growth, oxidative
stress, reduced cell viability, and shifts in differentiation toward or away from the dopamine (DA)
and acetylcholine (ACh) neurotransmitter phenotypes. 
RESULTS: In general, the rank order of adverse effects was PFOSA > PFOS > PFBS ≈ PFOA.
However, superimposed on this scheme, the various agents differed in their underlying mechanisms
and specific outcomes. Notably, PFOS promoted differentiation into the ACh phenotype at the
expense of the DA phenotype, PFBS suppressed differentiation of both phenotypes, PFOSA
enhanced differentiation of both, and PFOA had little or no effect on phenotypic speciﬁcation.
CONCLUSIONS: These ﬁndings indicate that all perﬂuorinated chemicals are not the same in their
impact on neurodevelopment and that it is unlikely that there is one simple, shared mechanism by
which they all produce their effects. Our results reinforce the potential for in vitro models to aid in
the rapid and cost-effective screening for comparative effects among different chemicals in the same
class and in relation to known developmental neurotoxicants.
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mechanisms problematic. Upon exposure to
nerve growth factor, PC12 cells gradually exit
the mitotic cycle and begin to differentiate,
developing axonal projections, electrical
excitability, and two distinct neurotransmitter
phenotypes, ACh and dopamine (DA) (Fujita
et al. 1989; Song et al. 1998; Teng and Greene
1994); this renders them particularly suitable
for examining whether the effects of PFOS and
PFOA on ACh systems reported in vivo
(Johansson et al. 2008) are likely to reflect
direct neurotoxic actions. Nevertheless, PC12
cells share the limitations common to in vitro
models, namely, difficulty in modeling neu-
ronal–glial or other cell-to-cell interactions, or
architectural aspects of regional development,
maternal–fetal or neonatal pharmacokinetics,
and related issues of bioavailability, dose, and
bioeffective concentrations (Costa 1998;
Slotkin 2004b).
We focused on four perﬂuorinated chemi-
cals: PFOS and PFOA, the agents for which
bioaccumulation is currently the highest;
perfluorooctane sulfonamide (PFOSA), a
potent mitochondrial toxicant (Starkov and
Wallace 2002) and less polar precursor to
PFOS, found in human tissues; and PFBS, a
representative of the newer PFAAs with much
shorter biologic half-lives (Lau et al. 2007).
The design of an appropriate concentration
range for in vitro studies is somewhat arbitrary,
given that we are using a transformed cell line
and that exposures occur over a very short
period (hours to days) as opposed to much
longer exposures in vivo (e.g., throughout ges-
tation, infancy, or childhood). We chose to
evaluate concentrations of 10–250 µM, lying
in the upper range of human serum levels (Lau
et al. 2007; Olsen et al. 1998, 1999, 2003a,
2003b). We also included a positive test sub-
stance for comparison with the perﬂuorinated
chemicals, as recommended for developmental
neurotoxicity testing so as to demonstrate the
capacity to identify signiﬁcant effects, as well as
to provide a benchmark for comparison to a
known developmental toxicant (Crofton et al.,
in press). For our purposes, we used chlorpyri-
fos (CPF), an organophosphate pesticide
whose developmental neurotoxicity has been
well-characterized both in vivo and in vitro
(Slotkin 1999, 2004a, 2005) and for which the
PC12 model recapitulates the underlying cellu-
lar mechanisms that operate in the intact,
developing brain (Bagchi et al. 1995;
Crumpton et al. 2000a; Das and Barone 1999;
Jameson et al. 2006b, 2007; Qiao et al. 2001;
Slotkin et al. 2007; Song et al. 1998). Our
evaluations were conducted for cells in both
the undifferentiated state and during differenti-
ation, focusing on indices of cell replication
(radiolabeled thymidine incorporation into
DNA), cell number (amount of DNA in the
culture), cell growth (total protein/DNA ratio,
membrane/total protein ratio), viability (trypan
blue exclusion), and phenotype (DA vs. ACh).
Each neural cell contains only a single nucleus
(Winick and Noble 1965), so the DNA con-
tent (micrograms of DNA per culture dish in
the present study) reﬂects the total number of
cells (Song et al. 1998). Indices of growth were
provided by measurements of protein subfrac-
tions related to cell size and membrane surface
area (Jameson et al. 2006a; Thai et al. 1996).
The total protein/DNA ratio rises with cell
enlargement and, with the onset of differentia-
tion, the development of neuritic projections
necessitates a rise in the relative contribution of
membrane proteins, so the increase in the
membrane/total protein ratio gives an indica-
tion of augmented membrane “complexity.”
The effects on cell number, size, and cell sur-
face area were compared to those on viability,
evaluated by trypan blue exclusion, and lipid
peroxidation, determined from the formation
of malondialdehyde (MDA). To characterize
the DA and ACh phenotypes, we assessed the
activities of the biosynthetic enzymes for these
two neurotransmitters, tyrosine hydroxylase
(TH) and choline acetyltransferase (ChAT),
respectively (Teng and Greene 1994).
Materials and Methods
All of the techniques used in this study have
been reported previously; thus, only brief
descriptions are given here.
Cell cultures. Because of the clonal instabil-
ity of the PC12 cell line (Fujita et al. 1989), the
experiments were performed on cells that had
undergone fewer than ﬁve passages. PC12 cells
(American Type Culture Collection, 1721-
CRL; obtained from the Duke Comprehensive
Cancer Center, Durham, NC) were grown
under standard conditions (Crumpton et al.
2000a; Qiao et al. 2003; Song et al. 1998) in
RPMI-1640 medium (Invitrogen, Carlsbad,
CA) supplemented with 10% inactivated horse
serum (Sigma Chemical Co., St. Louis, MO),
5% fetal bovine serum (Sigma), and 50 µg/mL
penicillin streptomycin (Invitrogen); cells were
incubated with 7.5% CO2 at 37°C. For studies
in the undifferentiated state, the medium was
changed 24 hr after seeding to include 50 µM
CPF (98.8% purity; Chem Service, West
Chester, PA), or varying concentrations of each
of the four perﬂuorinated chemicals (supplied
by Battelle, Columbus, OH): PFOS (97%
purity), PFOA (99.2% purity), PFOSA
(99.4% purity), and PFBS potassium salt
(98.2% purity). Because of the limited water
solubility of CPF and some of the perfluori-
nated chemicals, all test agents were dissolved
in dimethyl sulfoxide (DMSO) to achieve a
ﬁnal concentration in the culture medium of
0.1%, which has no effect on replication or
differentiation of PC12 cells (Qiao et al. 2001,
2003; Song et al. 1998); control cultures con-
tained the same concentration of DMSO. For
studies in differentiating cells, 24 hr after seed-
ing, the medium was changed to include
50 ng/mL of 2.5 S murine nerve growth factor
(Invitrogen) and DMSO with or without the
test agents; these cells were examined for up to
6 days, with medium changes (including test
agents) every 48 hr. We chose the CPF concen-
tration to elicit a robust response for each of the
effects to be compared to the actions of perﬂuo-
rinated chemicals, and accordingly, we selected
a concentration that elicits inhibition of DNA
synthesis and interference with cell acquisition
and oxidative stress, but that lies below the
threshold for outright cytotoxicity or loss of via-
bility (Bagchi et al. 1995; Crumpton et al.
2000b; Das and Barone 1999; Jameson et al.
2006b; Qiao et al. 2001, 2003, 2005; Slotkin
et al. 2007; Song et al. 1998).
DNA synthesis. We measured DNA synthe-
sis in undifferentiated cells. Twenty-four hours
after plating, we changed the medium to
include the test agents. After 23 hr of exposure,
we initiated the measurement of DNA synthesis
by changing the medium to include 1 µCi/mL
of [3H]thymidine (speciﬁc activity, 2 Ci/mmol;
GE Healthcare, Piscataway, NJ) along with the
continued inclusion of the test substances. After
1 hr, the medium was aspirated and cells were
harvested, and DNA was precipitated and sepa-
rated from other macromolecules by established
procedures that produce quantitative recovery
of DNA (Bell et al. 1986; Slotkin et al. 1984).
The DNA fraction was counted for radiolabel
and the DNA concentration was determined
spectrophotometrically by absorbance at
260 nm. We corrected incorporation values to
the amount of DNA present in each culture to
provide an index of DNA synthesis per cell
(Winick and Noble 1965), and we recorded the
total DNA content. 
DNA and protein ratios. We determined
DNA and protein ratios in differentiating cells
after 6 days of continuous exposure to the test
agents. Cells were harvested and washed, and
the DNA and protein fractions were isolated
and analyzed as described previously (Slotkin
et al. 2007; Song et al. 1998), with DNA and
total protein analyzed by dye binding (Trauth
et al. 2000). To prepare the cell membrane
fraction, the homogenates were sedimented at
40,000 × g for 10 min and the pellet was
washed and resedimented. Aliquots of the ﬁnal
resuspension were then assayed for membrane
protein (Smith et al. 1985).
Oxidative stress. We evaluated the degree
of lipid peroxidation in undifferentiated cells
after 24 hr of exposure to test agents, and in
differentiating cells after 4 days of exposure.
We measured the concentration of MDA by
reaction with thiobarbituric acid using a
modiﬁcation (Qiao et al. 2005) of published
procedures (Guan et al. 2003). To give the
MDA concentration per cell, values were cal-
culated relative to the amount of DNA.
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culture medium was changed to include try-
pan blue (1 volume per 2.5 vol of medium;
Sigma) and cells were examined for staining
under 400× magniﬁcation, counting an aver-
age of 100 cells per field in four different
fields per culture. Assessments were made
after 24 hr of exposure in undifferentiated
cells and after 4 days for differentiating cells.
Enzyme activities. Differentiating cells
were harvested after 6 days of exposure, as
described above, and were disrupted by
homogenization in a ground-glass homoge-
nizer fitted with a ground-glass pestle and
using a buffer consisting of 154 mM NaCl
and 10 mM sodium-potassium phosphate
(pH 7.4). Aliquots were withdrawn for meas-
urement of DNA (Trauth et al. 2000).
ChAT assays were conducted following
published techniques (Lau et al. 1988) using a
substrate of 50 µM [14C]acetyl–coenzyme A
(speciﬁc activity, 60 mCi/mmol; PerkinElmer
Life Sciences, Boston, MA). Labeled ACh was
counted in a liquid scintillation counter and
activity calculated as nanomoles synthesized
per hour per microgram DNA.
TH activity was measured using [14C]tyro-
sine as a substrate and trapping the evolved
14CO2 after coupled decarboxylation (Lau
et al. 1988; Waymire et al. 1971). Each assay
contained 0.5 µCi of generally labeled
[14C]tyrosine (speciﬁc activity, 438 mCi/mmol;
Sigma) as substrate, and activity was calculated
on the same basis as for ChAT.
Data analysis. All studies were performed
on 8–16 separate cultures for each measure
and treatment, using 2–4 separate batches of
cells. Results are presented as mean ± SE, with
treatment comparisons carried out by analysis
of variance (ANOVA) followed by Fisher’s
protected least significant difference test for
post hoc comparisons of individual treat-
ments. In the initial test, we evaluated two
ANOVA factors (treatment, cell batch) and
found that the results did not vary among the
different batches of cells, so results across the
different batches were combined for presenta-
tion. Signiﬁcance was assumed at p < 0.05.
Results
PFOS. In undifferentiated PC12 cells, PFOS
elicited a small but statistically significant
reduction in DNA synthesis within 24 hr of
exposure (Figure 1A). The effect was smaller
than that elicited by 50 µM CPF, even when
the PFOS concentration was raised to 250 µM.
None of the concentrations elicited a decre-
ment in the number of cells as monitored by
DNA content (Figure 1B). Nevertheless,
PFOS evoked a greater degree of lipid peroxi-
dation than did CPF (Figure 1C), with signiﬁ-
cant effects even at the lowest concentration
(10 µM). The effects were insufﬁcient to trig-
ger a loss of viability as monitored by trypan
blue exclusion (Figure 1D).
In differentiating cells, 6 days of exposure
to PFOS failed to cause any alterations in
indices of cell number (Figure 2A), size
Slotkin et al.
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Figure 2. Effects of perﬂuorinated chemicals on DNA content and protein ratios in differentiating PC12 cells after 6 days of exposure. (A) DNA content. (B) Total
protein/DNA ratio. (C) Membrane/total protein ratio. Values shown are mean ± SE of 8–16 determinations for each group. ANOVA across all treatments in a given
experiment is shown at the bottom of each panel. For comparison with the perfluorinated chemicals, 50 µM CPF was included as a positive test compound.
Determinations for 250 µM PFOSA were not performed in (B) and (C) because of the small number of cells remaining.
*Individual treatments differ signiﬁcantly from the corresponding control. 
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Figure 1. Effects of perﬂuorinated chemicals in undifferentiated PC12 cells after 24 hr of exposure. (A) DNA
synthesis. (B) DNA content. (C) Lipid peroxidation. (D) Cell viability evaluated with trypan blue. Abbreviations:
dpm, disintegrations per minute; NS, not signiﬁcant. Values shown are mean ± SE of 8–16 determinations for
each group. ANOVA across all treatments in a given experiment is shown at the bottom of each panel. In
(A, B, and C), 50 µM CPF was included as a positive test compound for comparison with the perﬂuorinated
chemicals; CPF does not decrease viability (Song et al. 1998) and was therefore not included in (D). 
*Individual treatments differ significantly from the corresponding control. The asterisks in parentheses for PFBS in (D)
denote signiﬁcant differences that were found in the post hoc test despite the absence of a signiﬁcant overall effect by
ANOVA; this was carried out because two-factor ANOVA (treatment, differentiation state) for trypan blue staining in both
the undifferentiated state and during differentiation (Figure 3B) indicated a significant main treatment effect (p < 0.02)
without a treatment × state interaction. 
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C D(Figure 2B), or the membrane outgrowth
associated with neurite formation (Figure 2C),
whereas the positive test compound, CPF,
showed significant reductions in DNA con-
tent and increments in both of the protein
ratios. Indices of lipid peroxidation and cell
viability were conducted after 4 days of expo-
sure, because these factors represent a forerun-
ner of cell loss. In contrast to the effects in
undifferentiated cells, PFOS evoked less
oxidative stress than did CPF (Figure 3A).
PFOS decreased cell viability only at the high-
est concentration (Figure 3B).
With the onset of differentiation, PC12
cells showed increased expression of both TH
(Figure 4A) and ChAT (Figure 4B), with a
much greater effect on the latter, so the
TH/ChAT ratio fell by nearly an order of mag-
nitude (Figure 4C). PFOS interfered with the
differentiation into the DA phenotype, as
evidenced by a decrement in TH that was sig-
niﬁcant at concentrations > 50 µM (Figure 4A).
At the same time, it enhanced expression of the
ACh phenotype, as shown by significant
increases in ChAT (Figure 4B); the effect
peaked at 50 µM PFOS and then declined,
thus displaying an “inverted-U” concentration–
effect relationship. The combination of reduced
TH and augmented ChAT produced a robust
net shift toward the ACh phenotype, as shown
by a significant reduction in the TH/ChAT
ratio, even at the lowest PFOS concentration
(Figure 4C).
PFOA. Unlike PFOS, 24 hr of exposure
of undifferentiated cells to PFOA produced
inhibition of DNA synthesis only at 250 µM,
the highest concentration tested (Figure 1A).
As before, there were no effects on DNA con-
tent (Figure 1B). PFOA also produced a sig-
niﬁcant overall increase in lipid peroxidation,
but the effect achieved statistical signiﬁcance
at only one concentration (10 µM); unlike
PFOS, the effect was smaller than for the pos-
itive test compound, CPF (Figure 1C). Cell
viability was signiﬁcantly reduced at the two
highest concentrations (Figure 1D), but the
effect was not statistically distinguishable
from the nonsignificant increase seen with
PFOS (no interaction of treatment × agent in
a two-factor ANOVA).
In differentiating cells, PFOA also proved
negative for effects on cell number, except at
the highest concentration (Figure 2A), and had
no discernible impact on the protein/DNA
ratio (Figure 2B) or the membrane/total pro-
tein ratio (Figure 2C); however, significant
effects were seen for all markers with CPF. The
differentiating cells also showed some evidence
of oxidative stress elicited by PFOA, albeit to a
lesser extent than for CPF (Figure 3A), and
there were no effects on cell viability as moni-
tored by trypan blue exclusion (Figure 3B).
Unlike PFOS, PFOA had only minor effects
on differentiation of PC12 cells into the DA
and ACh phenotypes. We observed a small
decrement in TH activity that was signiﬁcant
at only two of the four concentrations tested
(Figure 4A). There was no signiﬁcant overall
effect on ChAT (Figure 4B). The TH/ChAT
ratio similarly showed only a small but statisti-
cally signiﬁcant decrement at the lowest PFOA
concentration (Figure 4C).
PFOSA. The effects of PFOSA were sub-
stantially different from those of PFOS or
PFOA. In undifferentiated cells, PFOSA pro-
duced signiﬁcant inhibition of DNA synthesis
at all concentrations tested (Figure 1A). The
reduction was equivalent to that of CPF at
equimolar concentrations and then showed
progressively greater loss at higher concentra-
tions, so that at 250 µM PFOSA, DNA syn-
thesis was almost totally arrested. Even within
the span of the 24-hr exposure, 250 µM
PFOSA caused a 50% decrease in the number
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Figure 3. Effects of perfluorinated chemicals on cell damage markers in differentiating PC12 cells after
4 days of exposure. (A) Lipid peroxidation assessed by the MDA concentration. (B) Trypan blue staining of
nonviable cells. NS, not signiﬁcant. Values shown are mean ± SE of 8–16 determinations for each group.
ANOVA across all treatments in a given experiment is shown at the bottom of each panel. For comparison
with the perfluorinated compounds, 50 µM CPF was included as a positive test compound in (A), but
because CPF does not decrease viability (Song et al. 1998), it was not included in (B). 
*Individual treatments differ significantly from the corresponding control. The asterisk in parentheses in (B) denotes a
signiﬁcant difference that was found for PFBS in the post hoc test despite the absence of a signiﬁcant overall effect by
ANOVA; this was carried out because two-factor ANOVA (treatment, differentiation state) for trypan blue staining in both
the undifferentiated state (Figure 1D) and during differentiation indicated a significant main treatment effect (p < 0.02)
without a treatment × state interaction. 
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16 ± 2 17 ± 1 16 ± 1 3.7 ± 0.1* 17 ± 1of cells, as monitored by DNA content
(Figure 1B). Because this reduction occurred
in less than the doubling time for undifferen-
tiated PC12 cells (48–72 hr), it suggested that
there was an adverse effect on existing cells
rather than just inhibition of new cell forma-
tion. Indeed, we found a greater degree of
oxidative stress for PFOSA than for CPF,
even at one-fifth the concentration, and a
massive increase in lipid peroxidation at the
highest concentration (Figure 1C). The
effects were accompanied by a major decrease
in viability, indicated by a rise in trypan blue–
stained cells (Figure 1D).
In differentiating cells, 6 days of exposure
to PFOSA produced signiﬁcant decrements in
DNA content, with a near-total loss of cells at
the highest concentration (Figure 2A); accord-
ingly, protein ratios could not be evaluated at
250 µM. At 100 µM PFOSA, the remaining
cells showed a signiﬁcant increase in the pro-
tein/DNA ratio (Figure 2B), and there were
small increments in the membrane/total pro-
tein ratio that achieved signiﬁcance at 50 and
100 µM (Figure 2C). Because of the loss of
cells at 6 days, we evaluated indices of cell
damage at the 4-day point. Lipid peroxidation
was readily demonstrable at PFOSA concen-
trations > 10 µM, with a massive increase at
250 µM (Figure 3A), at which point loss of
viability was readily demonstrable (Figure 3B).
Assessments of the impact of PFOSA on
neurotransmitter phenotype were likewise
truncated at 100 µM since few cells survived
for 6 days at 250 µM. PFOSA had a promo-
tional effect on TH at 50 or 100 µM, reach-
ing three times control values at the higher
concentration (Figure 4A). Differentiation
into the ACh phenotype was also augmented
by PFOSA (Figure 4B). However, there was a
disparate concentration–effect relationship for
the two phenotypes: at low concentrations,
PFOSA shifted differentiation toward the
ACh phenotype, as evidenced by a decrease in
TH/ChAT, whereas at 100 µM, the effect on
the DA phenotype predominated, producing
a large increment in TH/ChAT (Figure 4C).
PFBS. The effects of PFBS were some-
what similar to those of PFOA. In undifferen-
tiated cells, there was little or no effect on
DNA synthesis (Figure 1A), no shortfall in cell
numbers (Figure 1B), and no signiﬁcant lipid
peroxidation (Figure 1C), although at high
concentrations there was a small loss of viabil-
ity (Figure 1D). Similarly, in differentiating
cells, PFBS did not evoke a reduction in DNA
content (Figure 2A), although it did produce
signiﬁcant cell enlargement as evidenced by an
increase in the total protein/DNA ratio
(Figure 2B). Like PFOA, PFBS did not
change the membrane/total protein ratio
(Figure 2C). PFBS evoked lipid peroxidation
in differentiating cells, of about the same mag-
nitude as that seen with PFOA but slightly less
than that of the positive test compound, CPF
(Figure 3A). Viability in differentiating cells
was not compromised until the PFBS concen-
tration was raised to 250 µM (Figure 3B).
Notably, though, PFBS had a unique effect on
differentiation into the two neurotransmitter
phenotypes, displaying a concentration-depen-
dent decrease in both the expression of TH
(Figure 4A) and ChAT (Figure 4B), a pattern
that was not seen with any other agent.
Accordingly, the ratio of TH/ChAT was
unchanged (Figure 4C) because both enzymes
were reduced in parallel by PFBS.
Discussion
To our knowledge, this is the ﬁrst demonstra-
tion that PFAAs do indeed have direct,
developmental neurotoxicant actions and that
they target speciﬁc events in neural cell differ-
entiation. In general, the rank order of adverse
effects was PFOSA > PFOS > PFBS ≈ PFOA.
However, superimposed on this scheme, the
various agents differed in their underlying
mechanisms and speciﬁc outcomes, indicating
that all PFAAs are not the same in their impact
on neurodevelopment and that it is unlikely
that there is one simple, shared mechanism by
which they all produce their effects.
The greater toxicity of PFOSA can be par-
tially attributed to its less hydrophilic nature.
Because the other agents are free acids (PFOA)
or sulfonic acids (PFOS, PFBS), PFOSA will
more readily cross the cell membrane, achiev-
ing higher intracellular levels. By itself, this
finding gives important information readily
translatable to developmental neurotoxicity
in vivo: PFAAs that are more hydrophobic or
that form less polar metabolites are likely to be
more problematic, especially since the same
physicochemical properties govern passage
across the placental and blood–brain barriers.
Nevertheless, pharmacokinetic differences can-
not account for the disparities in actions among
the various PFAAs: PFOS elicited larger
changes than PFBS, despite the fact that both
are sulfonic acids, and all four agents had differ-
ing, even opposite, actions on neurotransmitter
phenotypes. Certainly, one likely possibility for
the greater toxicity of PFOSA is its ability to
uncouple mitochondrial oxidative function,
whereas PFOS and PFOA act simply as surfac-
tants at the mitochondrial membrane (Starkov
and Wallace 2002). This feature may con-
tribute to disparities in the targeting of speciﬁc
events in cell differentiation that are affected by
oxidative stress and other downstream events
linked to mitochondrial dysfunction.
PFOSA was the only one of the agents
tested that matched or exceeded the ability of
CPF to inhibit DNA synthesis in undifferenti-
ated cells. Likewise, PFOSA elicited the great-
est degree of oxidative stress and cell loss,
regardless of whether cells were undifferenti-
ated or differentiating. Nevertheless, even with
PFOSA we did not see signiﬁcant loss of cell
viability until the concentration was raised to
250 µM, implying that there are factors other
than cytotoxicity that contribute to the net
effects. In fact, our results point to strong pro-
motion of the switch from cell replication to
cell differentiation, which would also con-
tribute to a reduction in DNA synthesis and
in cell numbers. The protein ratios provide
support for this interpretation. First, the pro-
tein/DNA ratio increased with PFOSA treat-
ment at concentrations below the threshold
for cytotoxicity, indicating an increase in cell
size rather than the suppression of growth
that would be expected from cytotoxic
actions. Second, the membrane/total protein
ratio also showed a rise with subtoxic PFOSA
treatments, indicating augmented membrane
complexity, which is commensurate with gen-
eration of neurites and cellular organelles that
accompanies differentiation. The ﬁnal proof of
a prodifferentiation effect can be seen from the
strong promotion of both neurotransmitter
phenotypes, evidenced by marked increases in
both TH and ChAT. The differentiation pat-
tern triggered by PFOSA is not, however, a
normal one: At low concentrations, the
TH/ChAT ratio was slightly, but signiﬁcantly
decreased, whereas at high concentrations, it
rose markedly. This means that PFOSA alters
the differentiation fate of the cells, switching
them weakly to the ACh phenotype at low
concentrations, and strongly to the DA pheno-
type at high concentrations. If similar effects
happen in vivo, it might be expected that neu-
rons will differentiate into inappropriate phe-
notypes; this would lead to miswiring of neural
circuits, with presynaptic projections for a
given neurotransmitter juxtaposed to post-
synaptic elements containing incorrect recep-
tors, resulting in nonfunctional synapses.
Given the biphasic dose–response curve, the
outcomes would be very different for an indi-
vidual exposed to low doses that promote the
ACh phenotype as opposed to an individual
receiving higher exposures that promote the
DA phenotype. Such switching has already been
seen with other agents that produce phenotype
shifts in the PC12 model, notably CPF (Barone
et al. 2000; Dam et al. 1999; Jameson et al.
2006b; Pope 1999; Rice and Barone 2000;
Slotkin 2004a; Vidair 2004). The biphasic
nature of the concentration–effect relationship
suggests that there are at least two separate
mechanisms operating to turn on expression of
neurotransmitter phenotypes. Oxidative stress,
which was prominent for PFOSA, is likely to
be one contributory factor, since oxidative
stress itself is a prodifferentiation signal (Katoh
et al. 1997). However, it is also possible that
PFOSA switches the phenotypes by turning
specific DA- or ACh-related genes on or off
inappropriately, as has been shown for the
organophosphates (Slotkin and Seidler 2007).
Slotkin et al.
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thesis in undifferentiated PC12 cells, its effects
were less than those seen with the positive test
compound (CPF) and far smaller than those
seen with PFOSA. There was no parallel
reduction in DNA content, which is not sur-
prising given the small effect on DNA synthe-
sis and the fact that a 24-hr exposure is less
than a doubling time for PC12 cell replica-
tion. Notably, we did not ﬁnd any reductions
in cell numbers even with a 6-day exposure of
differentiating cells, showing that the effects of
PFOS are indeed fundamentally different
from those of PFOSA. This was further con-
ﬁrmed by a lack of any evidence for a global
prodifferentiation effect because there were no
changes in the protein ratios and only a small
degree of oxidative stress. Nonetheless, PFOS
altered the phenotypic fate of the cells, pro-
moting the ACh phenotype at the expense of
the DA phenotype; the effect was again bipha-
sic, as the increase in ChAT regressed back to
normal as the PFOS concentration was raised
above the point where lipid peroxidation and
cytotoxicity emerged. There are two impor-
tant points made by these findings: a) The
impact of PFOS on neurotransmitter pheno-
type is radically different from that of PFOSA;
and b) some of the effects on differentiation
are distinct from those related to oxidative
stress and cytotoxicity, and occupy a part of
the concentration–effect curve below the
thresholds for those common adverse events.
Of the four agents, PFOA and PFBS had
the least effect on most of the parameters con-
noting cell acquisition and growth. Neither
agent produced any substantial inhibition of
DNA synthesis or cell loss in undifferentiated
cells, and a small decrease in DNA in differ-
entiating cells was found only at the highest
concentration, and only for PFOA. Although
both agents produced small but significant
decreases in viability at concentrations of
100 or 250 µM, the effect was obviously
insufficient to have any impact on the total
number of cells remaining in the culture.
Similarly, PFOA had no effect on protein
ratios, and PFBS had only a small effect on
total protein/DNA without any impact on
membrane/total protein. For phenotypic out-
comes, the two agents were substantially dif-
ferent from PFOSA and PFOS, both in the
type and magnitude of effects. PFOA caused
a slight reduction in TH and, consequently, a
minor shift favoring the ACh phenotype
(reduced TH/ChAT ratio). In contrast, PFBS
retarded differentiation into both phenotypes,
an effect not seen with any other agent;
accordingly, although the TH/ChAT ratio
was unaffected by PFBS, both TH and ChAT
were signiﬁcantly reduced, indicating a likeli-
hood of impaired function for both neuro-
transmitters. Once again, this demonstrates
that the effect on phenotypic fate of the cells
is distinct from any other effects on cell repli-
cation, growth, or viability.
Our results thus point to the potential for
PFAAs to evoke developmental neurotoxicity
through direct actions on replicating and differ-
entiating neurons, effects distinct from the indi-
rect consequences of endocrine disruption or
metabolic or other secondary mechanisms.
Importantly, the various PFAAs differ not only
in their propensity to elicit outright neurot-
oxicity or oxidative stress but also in their ability
to augment or suppress specific neuro-
transmitter phenotypes, thus shifting the differ-
entiation fate of the neuron. These effects can
even be in opposite directions for the various
PFAAs, and because the concentration–effect
curve is biphasic, different levels of exposure
can be expected to produce disparate outcomes
directed toward a given neurotransmitter phe-
notype. The fact that there are stark differences
in developmental neurotoxicant actions among
otherwise similar PFAAs means that it is impor-
tant to take developmental neurotoxicity into
account in the design of future members of this
class. As demonstrated here, this can be aided
by the use of in vitro models that permit rapid
and cost-effective screening for developmental
neurotoxicity.
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